Allogene Therapeutics ALLO Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $131.96M-12.1% | $150.15M-9.8% | $166.49M-7.5% | $180.04M-5.4% | $190.24M-1.1% | ||
| $55.88M-1.6% | $56.78M-3.0% | $58.53M-4.2% | $61.12M-2.9% | $62.93M-3.5% | ||
| $190.22M-9.1% | $209.32M-8.0% | $227.4M-10.6% | $254.27M-5.4% | $268.89M-1.6% | ||
| -$190.22M+9.1% | -$209.32M+8.0% | -$227.4M+10.6% | -$254.27M+5.4% | -$268.89M+1.6% | ||
| $1.23M+14.0% | $1.08M+27.5% | $843K+40.7% | $599K+81.0% | $331K+82.9% | ||
| $16.46M-10.7% | $18.43M+16.4% | $15.83M-11.1% | $17.81M+4.7% | $17.01M+5.9% | ||
| -$173.76M+9.0% | -$190.89M+10.0% | -$212.02M+10.5% | -$236.91M+6.1% | -$252.32M+2.0% | ||
| -$0.77+11.5% | -$0.87+11.2% | -$0.98+11.7% | -$1.11+9.8% | -$1.23+7.5% | ||
| -$178.09M+9.6% | -$196.96M+8.3% | -$214.87M+11.1% | -$241.63M+5.5% | -$255.7M+1.5% | ||
| -$190.22M+9.1% | -$209.32M+8.0% | -$227.4M+10.6% | -$254.27M+5.4% | -$268.89M+1.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Allogene Therapeutics profitable?
- Allogene Therapeutics is not currently profitable: it reported a net loss of $173.8M over the trailing twelve months, a -1170863.6% net margin.
- What is Allogene Therapeutics's earnings per share?
- Allogene Therapeutics's diluted EPS over the trailing twelve months is $-0.77.
- Where does Allogene Therapeutics's income statement data come from?
- Every line is extracted from Allogene Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.